Symposium to be held at European Society of Cardiology 2018 Meeting
Saturday, August 25, 2018: 15:30 – 16:30 hrs (Munich, Germany time)
Agenda
Introduction, Ulrich Laufs, MD, University of Leipzig Medical Center, Leipzig, Germany
The real residual risk in patients with CVD & diabetes: The promise of epigenetics, Erik Stroes, MD, Academic Medical Centre, Amsterdam, The Netherlands
Understanding Epigenetics: The potential rationale for BET inhibition in management of CVD, Jorge Plutzky, MD, Brigham & Women’s Hospital, Boston, USA
A clinical view on BET inhibition in targeting residual risk in CVD and Diabetes , Kausik Ray, MD, Imperial College London, London, United Kingdom
"Apabetalone (RVX-208) Reduces Monocyte-Endothelial Cell Adhesion and Expression of Key Vascular Inflammation Markers in Monocytes, Endothelial Cells and in Inflamed Mouse Aorta."
Ewelina Kulikowski from Resverlogix will present the above oral late breaker presentation on Monday August 27th This title seems very similar to abstract 257 presented by Resverlogix at Vascular Discovery 2018 back May 10-12, 2018. There will very likely be some new stuff in upcoming August ESC presentation since the submission deadline for Vascular Discovery was Jan 10, 2018 and late breaker submission deadline for ESC was April 4th, 2018.
